Th1 responses are more susceptible to infliximab-mediated immunosuppression than Th17 responses

Kenji Kanayama, Kazuhiko Nakamura, Haruei Ogino, Yorinobu Sumida, Eikichi Ihara, Hirotada Akiho, Ryoichi Takayanagi

Research output: Contribution to journalReview articlepeer-review

5 Citations (Scopus)

Fingerprint

Dive into the research topics of 'Th1 responses are more susceptible to infliximab-mediated immunosuppression than Th17 responses'. Together they form a unique fingerprint.

Medicine and Dentistry

Immunology and Microbiology

Neuroscience